NZ760036A - Dihydro-pyrrolo-pyridine derivatives - Google Patents
Dihydro-pyrrolo-pyridine derivativesInfo
- Publication number
- NZ760036A NZ760036A NZ760036A NZ76003618A NZ760036A NZ 760036 A NZ760036 A NZ 760036A NZ 760036 A NZ760036 A NZ 760036A NZ 76003618 A NZ76003618 A NZ 76003618A NZ 760036 A NZ760036 A NZ 760036A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- pyrrolo
- dihydro
- pyridine derivatives
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present invention provides, in part, compounds of Formula I, or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N- oxide, wherein: (R1)a, (R2)b, (R3)c, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4- associated) disorders including, e.g., Alzheimer’s Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
Claims (9)
1. A compound having the structure: (+/-)-trans- , or a pharmaceutically acceptable salt thereof.
2. The nd of claim 1, wherein the compound is: (+/-)-trans- .
3. The compound of claim 1, wherein the compound is a pharmaceutically acceptable salt of: (+/-)-trans- .
4. A compound having the structure: (+)-trans- , or a pharmaceutically able salt thereof.
5. The compound of claim 4, wherein the compound is: (+)-trans- .
6. The compound of claim 4, wherein the compound is a pharmaceutically acceptable salt of: (+)-trans- .
7. A compound having the structure: (-)-trans- , or a pharmaceutically acceptable salt thereof.
8. The compound of claim 7, wherein the compound is ans- .
9. The compound of claim 7, wherein the compound is a pharmaceutically acceptable salt of: (-)-trans- .
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523306P | 2017-06-22 | 2017-06-22 | |
| PCT/IB2018/054390 WO2018234953A1 (en) | 2017-06-22 | 2018-06-14 | Dihydro-pyrrolo-pyridine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ760036A true NZ760036A (en) | 2025-05-30 |
| NZ760036B2 NZ760036B2 (en) | 2025-09-02 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| IL271290A (en) | 2020-01-30 |
| HUE060914T2 (en) | 2023-04-28 |
| KR20200013783A (en) | 2020-02-07 |
| CN110944998A (en) | 2020-03-31 |
| EP3642202A1 (en) | 2020-04-29 |
| BR112019026955A2 (en) | 2020-06-30 |
| JP2020524687A (en) | 2020-08-20 |
| US11198692B2 (en) | 2021-12-14 |
| DK3642202T3 (en) | 2023-01-30 |
| CN110944998B (en) | 2022-08-16 |
| IL271290B2 (en) | 2023-11-01 |
| PL3642202T3 (en) | 2023-03-13 |
| FI3642202T3 (en) | 2023-03-01 |
| IL271290B1 (en) | 2023-07-01 |
| TW201920166A (en) | 2019-06-01 |
| US20200262833A1 (en) | 2020-08-20 |
| ES2937236T3 (en) | 2023-03-27 |
| JP7263266B2 (en) | 2023-04-24 |
| WO2018234953A1 (en) | 2018-12-27 |
| PT3642202T (en) | 2023-02-02 |
| SG11201913014YA (en) | 2020-01-30 |
| AU2018287787A1 (en) | 2020-01-16 |
| TWI680128B (en) | 2019-12-21 |
| CA3066986A1 (en) | 2018-12-27 |
| EP3642202B1 (en) | 2022-11-02 |
| MX2019015371A (en) | 2020-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500004A1 (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
| MX2019015371A (en) | Dihydro-pyrrolo-pyridine derivatives. | |
| MX2022012317A (en) | Oxysterols and methods of use thereof. | |
| MX2020013099A (en) | Heteroaromatic compounds and their use as dopamine d1 ligands. | |
| JOP20190151B1 (en) | Amino-triazolopyridine compounds and their use in cancer treatment | |
| EA201890650A1 (en) | DERIVATIVES 8- [6- [3- (amino) propoxy] -3-pyridyl] -1-ISOPROPYL-imidazo [4,5-c] quinolin-2-one as selective modulators of kinase MUTATION ataxia-telangiectasia (ATM) FOR CANCER TREATMENT | |
| PH12016502168A1 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MX2018005445A (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer. | |
| EA201691428A1 (en) | BICYCLIC HETEROCYCLIC DERIVATIVES AS IRAK4 INHIBITORS | |
| GEP201706780B (en) | Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c | |
| GEP20217248B (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
| PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| TW201613890A (en) | Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators | |
| GEP201706608B (en) | 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases | |
| PE20130010A1 (en) | DERIVATIVE OF 1,3,4,8-TETRAHIDRO-2H-PIRIDO [1,2-A] PIRAZINE AS AN INHIBITOR OF HIV INTEGRASE | |
| MX2009011830A (en) | Amino-heterocyclic compounds. | |
| MX2020011652A (en) | 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions. | |
| SA519401322B1 (en) | Heteroaryl carboxamide compounds as inhibitors of receptor-interacting serine/threonine protein kinase 2 | |
| GEAP202215499A (en) | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | |
| PH12020550168A1 (en) | Griseofulvin compound and pharmaceutical use thereof | |
| MX2019010756A (en) | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors. | |
| EA201692260A1 (en) | 1,3,4-TIADIAZOLE COMPOUNDS AND THEIR APPLICATION IN CANCER TREATMENT | |
| PH12017501699B1 (en) | Fused bicyclic heteroaryl derivatives having activity as phd inhibitors | |
| ZA201805790B (en) | Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and "azd9291 aniline" or a salt thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |